Matthew Daniels

Company: Accent Therapeutics

Job title: Associate Director

Seminars:

DHX9 Inhibitors as Novel Therapeutic Modalities in MSI-High Cancers 3:00 pm

DHX9 is an RNA helicase with important roles in replication, transcription, translation, RNA splicing and RNA processing Microsatellite instable high (MSI-high) cancer cell lines are selectively dependent on DHX9 activity Potent inhibitors of DHX9 have been identified that show antiproliferative activity in MSIhigh cancer models in vitro and in vivoRead more

day: Day Two